We designed several HIV protease inhibitors with various d-cysteine derivatives as P(2)/P(3) moieties based on the structure of clinical drug candidate, KNI-764. Herein, we report their synthesis, HIV protease inhibitory activity, HIV IIIB cell inhibitory activity, cellular toxicity, and inhibitory activity against drug-resistant HIV strains. KNI-1931 showed distinct selectivity against HIV proteases and high potency against drug-resistant strains, surpassing those of Ritonavir and Nelfinavir.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmcl.2007.05.039 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!